Swipe Left For English News
中国上海,
2024年1月11日
全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）宣布旗下生物新药研发服务部（CRDMO中的R—研究服务）与致力于为癌症和其他严重疾病研发创新疗法的新一代免疫疗法公司BioNTech（纳斯达克股票代码: BNTX）达成一项研究服务协议。
根据协议，药明生物通过其专利技术平台（CRDMO中的R—研究服务）为BioNTech开发针对两个未披露靶点抗体，用于研发新一代候选药物。药明生物将获得2000万美元首付款，并有资格获得研究、开发、注册和商业化里程碑付款以及分级销售提成。
陈智胜博士
首席执行官
药明生物
药明生物独特的CRDMO商业模式再次获得力证。我们非常高兴通过公司领先的一体化生物药发现技术平台，为BioNTech创新生物药产品管线注入强劲动能。这一协议不仅体现了公司持续获得全球合作伙伴认可，引领生物药发现服务，也再次证明了公司一体化生物药发现技术平台助力全球合作伙伴研发创新产品的能力。我们期待赋能BioNTech早日将这些潜力疗法惠及病患，为更多全球患者带来新的治疗希望。
药明生物通过行业领先的技术平台和全面的研究能力，提供从概念到临床前候选药物的全方位端到端和模块化的生物药发现服务。公司用于发现、筛选、优化和鉴定抗体与生物药的技术平台包括杂交瘤技术、单B细胞克隆技术、噬菌体展示和酵母展示技术、全人天然抗体文库和VHH免疫文库、全人源抗体转基因鼠平台（通过OmniAb®和Alloy Therapeutics合作）、双/多特异性抗体技术（WuXiBody™和SDarBody™等），以及其他生物药生成和优化技术。公司各种的生物材料研发能力和检测能力为技术平台提供重要的支撑。
推荐阅读
新闻速递 | 前沿洞见 | 精彩活动
关于药明生物
药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）服务公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物人的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2023年12月底，药明生物帮助客户研发和生产的综合项目高达698个，其中包括24个商业化生产项目。
药明生物将环境、社会和治理（ESG）视为业务发展和企业精神的重要组成部分，并致力于成为全球生物药CRDMO领域的ESG领导者，例如应用更绿色环保的新一代生物制药技术和能源等引领行业发展。公司成立了由首席执行官领导的ESG委员会，全面落实ESG战略并践行可持续性发展承诺。
更多信息，请访问：www.wuxibiologics.com
媒体关系 PR@wuxibiologics.com
业务垂询 info@wuxibiologics.com
WuXi Biologics Announces Research Service Agreement with BioNTech on Discovering Investigational Monoclonal Antibodies for Developing Next-Generation Therapeutic Product Candidates
Shanghai,
January 11, 2024
WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that its Research Service Unit (R in CRDMO) has signed a research service agreement with BioNTech SE (Nasdaq: BNTX, "BioNTech"), a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases.
Under the terms of the agreement, WuXi Biologics leverages its proprietary antibody discovery technology platforms (R in CRDMO) to discover two undisclosed targets of preclinical investigational monoclonal antibodies for BioNTech to develop next-generation therapeutic product candidates. WuXi Biologics will receive a $20 million upfront payment for granting exclusive rights to these investigational monoclonal antibodies to BioNTech and is eligible to receive additional payments, including payments for research, development, regulatory, and commercial milestones, as well as tiered royalties.
Dr. Chris Chen
CEO
WuXi Biologics
Our unique CRDMO model is proven again. We are very pleased to support BioNTech's growing innovative pipeline with antibodies discovered through our leading integrated discovery platforms. This agreement demonstrates our continued recognition as an industry leader in discovery service solutions, and further validates our ability to provide integrated discovery technology platforms for global partners to develop new modalities. We are looking forward to working with BioNTech with the aim of bringing potential new therapeutics with improved outcomes to patients worldwide.
WuXi Biologics offers a full spectrum of both end-to-end and modular discovery services – from idea to preclinical candidate identification – using industry-leading technology platforms and comprehensive discovery capabilities. The company's discovery technology platforms for the generation, characterization, engineering, optimization and selection of novel antibody and biologic therapeutics include: hybridoma technology; single B cell cloning technology; phage display and yeast display technology; immune and synthetic human scFv and VHH libraries; human IgG transgenic platforms through an OmniAb® and Alloy partnership; WuXiBody™ and SDarBody™ bispecific/multispecific antibody platforms; and other antibody and biologics generation and optimization technologies. All technology platforms are supported by WuXi Biologics' comprehensive research material generation and assay development capabilities.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2023, WuXi Biologics is supporting 698 integrated client projects, including 24 in commercial manufacturing.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
Contacts
Business
info@wuxibiologics.com
Media
PR@wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
